AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

Blood Cancer Journal

Volumn 1, Issue 11, 2011, Pages

  Yao, H ^a   Ashihara, E ^a,b   Strovel, J W ^c   Nakagawa, Y ^a   Kuroda, J ^b   Nagao, R ^a   Tanaka, R ^a   Yokota, A ^a   Takeuchi, M ^a   Hayashi, Y ^a   Shimazaki, C ^b   Taniwaki, M ^b   Strand, K ^c   Padia, J ^c   Hirai, H ^a   Kimura, S ^d   Maekawa, T ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c PGx Health   (United States)

^d SAGA UNIVERSITY   (Japan)

Author keywords

catenin; High throughput screening; Multiple myeloma; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; AV 65; BETA CATENIN; CYCLIN D1; MYC PROTEIN; SURVIVIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; EXPERIMENTAL MODEL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; RNA INTERFERENCE; WNT SIGNALING PATHWAY;

EID: 84863921921     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.41     Document Type: Article

References (40)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187. (Pubitemid 37328787)
2. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
3. Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107: 397-403. (Pubitemid 43053569)
4. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
5. Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A. Investigational treatments for multiple myeloma. Expert Opin Investig Drugs 2006; 15: 1565-1582. (Pubitemid 44848980)
6. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598. (Pubitemid 47106630)
7. Rajkumar SV. Treatment of myeloma: cure vs control. Mayo Clin Proc 2008; 83: 1142-1145.
8. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
9. Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000; 268: 243-248. (Pubitemid 30119606)
10. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419. (Pubitemid 37296260)
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512. (Pubitemid 28425575)
12. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426. (Pubitemid 29180374)
13. Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13: 4042-4045. (Pubitemid 47105963)
14. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101: 6122-6127. (Pubitemid 38520538)
15. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-7521. (Pubitemid 47185938)
16. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K et al. {beta}-Catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 2009; 15: 2731-2738.
17. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21: 2527-2536. (Pubitemid 350148897)
18. Bol D, Ebner R. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. Pharmacogenomics 2006; 7: 227-235.
19. Strand KJ, Khalak H, Strovel JW, Ebner R, Augustus M. Expression biomarkers for clinical efficacy and outcome prediction in cancer. Pharmacogenomics 2006; 7: 105-115.
20. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986; 46: 5125-5130. (Pubitemid 16008277)
21. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003; 102: 2229-2235. (Pubitemid 37122403)
22. Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R et al. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 2008; 7: 2904-2912.
23. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al. The BH3-only protein bid is dispensable for DNA damageand replicative stress-induced apoptosis or cell-cycle arrest. Cell 2007; 129: 423-433. (Pubitemid 46574974)
24. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S et al. Sulindac metabolites induce caspase- and proteasomedependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2003; 2: 885-892.
25. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 1997; 16: 4531-4539. (Pubitemid 27326590)
26. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003; 4: 609-615. (Pubitemid 36939953)
27. Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005; 113: 515-524. (Pubitemid 40038726)
28. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001; 61: 8664-8667. (Pubitemid 34013874)
29. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000; 1: 116-125.
30. Spring DR. Chemical genetics to chemical genomics: small molecules offer big insights. Chem Soc Rev 2005; 34: 472-482. (Pubitemid 40880427)
31. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51. (Pubitemid 46109296)
32. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betacatenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701. (Pubitemid 39150127)
33. Daniels DL, Eklof Spink K, Weis WI. Beta-catenin: molecular plasticity and drug design. Trends Biochem Sci 2001; 26: 672-678. (Pubitemid 33042490)
34. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300. (Pubitemid 36418379)
35. Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol 2007; 13: 6581-6587.
36. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001; 20: 645-653. (Pubitemid 32156189)
37. Hawcroft G, D'Amico M, Albanese C, Markham AF, Pestell RG, Hull MA. Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002; 23: 107-114. (Pubitemid 34213559)
38. Easwaran V, Pishvaian M, Salimuddin, Byers S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999; 9: 1415-1418.
39. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F et al. Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex. Cancer Cell 2004; 5: 91-102. (Pubitemid 38121599)
40. Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S et al. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. Leukemia 2007; 21: 535-540.